Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price dropped 10.1% on Friday . The company traded as low as $3.63 and last traded at $3.63. Approximately 1,146,264 shares traded hands during trading, a decline of 18% from the average daily volume of 1,391,843 shares. The stock had previously closed at $4.04.
Autolus Therapeutics Price Performance
The company's 50-day moving average is $3.99 and its 200-day moving average is $4.02. The firm has a market cap of $992.52 million, a price-to-earnings ratio of -3.22 and a beta of 2.04. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Equities research analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.
Institutional Trading of Autolus Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC bought a new stake in Autolus Therapeutics during the 2nd quarter worth approximately $43,000. Daiwa Securities Group Inc. lifted its holdings in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after buying an additional 15,293 shares during the period. Herbst Group LLC bought a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at about $91,000. Bayesian Capital Management LP acquired a new stake in shares of Autolus Therapeutics in the first quarter valued at about $100,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Autolus Therapeutics during the first quarter worth about $108,000. Institutional investors and hedge funds own 72.83% of the company's stock.
About Autolus Therapeutics
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
